Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
BeOne Medicines
Amgen
Merck Sharp & Dohme LLC
Daiichi Sankyo
Pierre Fabre Medicament
Freenome Holdings Inc.
Bristol-Myers Squibb
NantCell, Inc.
Sotio Biotech Inc.
Alaunos Therapeutics
Vedanta Biosciences, Inc.
Eisai Inc.
Incyte Corporation
Bristol-Myers Squibb
Bristol-Myers Squibb
Day One Biopharmaceuticals, Inc.
Enterome
Sanofi
Merck Sharp & Dohme LLC
Elicio Therapeutics
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Trishula Therapeutics, Inc.
Sotio Biotech Inc.
Bristol-Myers Squibb
SafeHeal Inc
Gilead Sciences
Nektar Therapeutics
Hoffmann-La Roche
Pfizer
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
Mirror Biologics, Inc.
Hutchmed
Menarini Group
Redx Pharma Ltd
Hutchmed
Elevation Oncology
HiberCell, Inc.
Boehringer Ingelheim
Cardiff Oncology
Merck Sharp & Dohme LLC
Pfizer
ImmunityBio, Inc.
Seagen Inc.
Immodulon Therapeutics Ltd
Merck Sharp & Dohme LLC